No public notification of MRSA outbreak among infants at UC Irvine

Ten infants being treated at UC Irvine Medical Center’s neonatal intensive care unit (NICU) have been infected with methicillin-resistant Staphylococcus aureus, or MRSA, over the course of eight months, but the hospital did not report the outbreak to patients preparing to deliver babies at the facility.

The Los Angeles Times said UC Irvine only confirmed the outbreak after reporters learned of it from Marian Hollingsworth, a patient safety advocate who filed a complaint with state regulators.

“You never know if your baby will end up in the NICU,” Hollingswroth said. “I would have wanted to know.”

UC Irvine said it didn’t believe public notification was necessary after the infected patients were isolated in another unit, with new patients only being admitted to its other NICU. None of the infants died from the infections, the hospital said, and there’s been no active infections since March 26.

Read the full article below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.